Transparency in decision modelling: what, why, who and how?

CJ Sampson, R Arnold, S Bryan, P Clarke, S Ekins… - …, 2019 - Springer
Transparency in decision modelling is an evolving concept. Recently, discussion has moved
from reporting standards to open-source implementation of decision analytic models …

[HTML][HTML] Making health economic models Shiny: A tutorial

R Smith, P Schneider - Wellcome open research, 2020 - ncbi.nlm.nih.gov
Health economic evaluation models have traditionally been built in Microsoft Excel, but more
sophisticated tools are increasingly being used as model complexity and computational …

A need for change! A coding framework for improving transparency in decision modeling

F Alarid-Escudero, EM Krijkamp, P Pechlivanoglou… - …, 2019 - Springer
The use of open-source programming languages, such as R, in health decision sciences is
growing and has the potential to facilitate model transparency, reproducibility, and …

R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study

R Hart, D Burns, B Ramaekers, S Ren, D Gladwell… - …, 2020 - Springer
Introduction Health economics models are typically built in Microsoft Excel® owing to its
wide familiarity, accessibility and perceived transparency. However, given the increasingly …

Developing open-source models for the US health system: practical experiences and challenges to date with the open-source value project

JP Jansen, D Incerti, MT Linthicum - Pharmacoeconomics, 2019 - Springer
Abstract The Innovation and Value Initiative started the Open-Source Value Project with the
aim to improve the credibility and relevance of model-based value assessment in the context …

Fault diagnosis for rolling bearing based on parameter transfer Bayesian network

Z Jiang, J Zhou, Y Ma - Quality and Reliability Engineering …, 2022 - Wiley Online Library
At the beginning of the change in bearing condition, the bearing fault features are weak,
often drowning in the background noise. It makes difficult to extract weak fault features from …

Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in China: A cost-effectiveness analysis based on a mapping algorithm derived from a Chinese …

C Tan, S Li, L Yi, X Zeng, L Peng, S Qin, L Wang… - Advances in …, 2021 - Springer
Introduction To estimate the cost-effectiveness of tofacitinib for patients with moderate-to-
severe rheumatoid arthritis (RA) who failed conventional synthetic disease-modifying …

Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis

C Tan, X Luo, S Li, L Yi, X Zeng, L Peng, S Qin… - Clinical …, 2022 - Springer
Background Biologic disease-modifying antirheumatic drugs (bDMARDs) are recommended
to be added in sequentially in the treatment of moderate-to-severe rheumatoid arthritis (RA) …

Cost-effectiveness of triple therapy vs. Biologic treatment sequence as first-line therapy for rheumatoid arthritis patients after methotrexate failure

SN Li, JH Li, LB Peng, YM Li, XM Wan - Rheumatology and Therapy, 2021 - Springer
Introduction A clinical trial (RACAT) reported the noninferiority of triple therapy compared to
biologic agents (etanercept+ methotrexate), and previous studies confirmed that biologic …

Transparency in health economic modeling: options, issues and potential solutions

EQ Wu, ZY Zhou, J Xie, C Metallo, P Thokala - PharmacoEconomics, 2019 - Springer
Economic models are increasingly being used by health economists to assess the value of
health technologies and inform healthcare decision making. However, most published …